Gilead Sciences, Inc. (GILD) Return on Assets (ROA): 16.38%
Is Gilead Sciences, Inc.’s return on assets (ROA) high or low?
Gilead Sciences, Inc.'s return on assets (ROA) of 16.38% is 140% above its 5-year average of 6.83%, near the high end of its 5-year range (0.18%–14.42%).
The return on assets (ROA) for Gilead Sciences, Inc. (GILD) is 16.38% as of Wednesday, June 10, 2026. It is above its 12-month average by 115.10% (7.62%).
GILD Return on Assets (ROA) Chart
GILD Average Return on Assets (ROA) Chart
GILD Current vs Average Return on Assets (ROA) Chart
GILD Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
16.38%
RETURN ON ASSETS (ROA) AVG TTM
7.62%
RETURN ON ASSETS (ROA) AVG 3Y
7.90%
RETURN ON ASSETS (ROA) AVG 5Y
6.83%
RETURN ON ASSETS (ROA) AVG 10Y
11.23%
RETURN ON ASSETS (ROA) AVG 15Y
14.10%
RETURN ON ASSETS (ROA) AVG 20Y
14.35%
CURRENT VS TTM AVG
+115.10%
CURRENT VS 3Y AVG
+107.21%
CURRENT VS 5Y AVG
+139.94%
CURRENT VS 10Y AVG
+45.82%
CURRENT VS 15Y AVG
+16.21%
CURRENT VS 20Y AVG
+14.13%
GILD Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | — | 16.38% | 7.62% | 7.90% | 6.83% |
| Abbott Laboratories (ABT) | $154.66B | 5.68% | 11.99% | 10.28% | 9.45% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 14.81% | 13.09% | 12.00% | 11.68% |
| Pfizer Inc. (PFE) | $146.36B | 3.61% | 3.75% | 6.08% | 7.08% |
| Danaher Corporation (DHR) | $130.25B | 4.42% | 4.68% | 5.89% | 6.01% |
| CVS Health Corporation (CVS) | $125.16B | 1.16% | 1.25% | 1.93% | 2.38% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 6.05% | 6.31% | 6.46% | 7.20% |
| Amgen Inc. (AMGN) | $183.75B | 8.43% | 6.48% | 7.48% | 8.52% |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 8.41% | -0.92% | 3.28% | 1.99% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 16.38% | 6.37% | 11.74% | 14.58% |
Asset Efficiency
ROA
16.4%
ROE
39.2%
Gilead Sciences, Inc. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gilead Sciences, Inc. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for Gilead Sciences, Inc. (GILD)?
- The return on assets (ROA) for GILD stock is 16.38%.
- Is Gilead Sciences, Inc.'s return on assets (ROA) high or low?
- Gilead Sciences, Inc.'s return on assets (ROA) of 16.38% is 140% above its 5-year average of 6.83%, near the high end of its 5-year range (0.18%–14.42%).
- What is the TTM average return on assets (ROA) for Gilead Sciences, Inc. (GILD)?
- The TTM average return on assets (ROA) for GILD stock is 7.62%.
- What is the 3Y average return on assets (ROA) for Gilead Sciences, Inc. (GILD)?
- The 3Y average return on assets (ROA) for GILD stock is 7.90%.
- What is the 5Y average return on assets (ROA) for Gilead Sciences, Inc. (GILD)?
- The 5Y average return on assets (ROA) for GILD stock is 6.83%.
- What is the 10Y average return on assets (ROA) for Gilead Sciences, Inc. (GILD)?
- The 10Y average return on assets (ROA) for GILD stock is 11.23%.
- What is the 15Y average return on assets (ROA) for Gilead Sciences, Inc. (GILD)?
- The 15Y average return on assets (ROA) for GILD stock is 14.10%.
- What is the 20Y average return on assets (ROA) for Gilead Sciences, Inc. (GILD)?
- The 20Y average return on assets (ROA) for GILD stock is 14.35%.
Gilead Sciences, Inc. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 14.42% |
| 2024-12-31 | 0.81% |
| 2023-12-31 | 9.12% |
| 2022-12-31 | 7.27% |
| 2021-12-31 | 9.16% |
| 2020-12-31 | 0.18% |
| 2019-12-31 | 8.74% |
| 2018-12-31 | 8.57% |
| 2017-12-31 | 6.58% |
| 2016-12-31 | 23.70% |
| 2015-12-31 | 35.01% |
| 2014-12-31 | 34.91% |
| 2013-12-31 | 13.62% |
| 2012-12-31 | 12.20% |
| 2011-12-31 | 16.20% |
| 2010-12-31 | 25.03% |
| 2009-12-31 | 27.18% |
| 2008-12-31 | 28.53% |
| 2007-12-31 | 27.68% |
| 2006-12-31 | -29.12% |
| 2005-12-31 | 21.61% |
| 2004-12-31 | 20.84% |
| 2003-12-31 | -4.63% |
| 2002-12-31 | 5.60% |
| 2001-12-31 | 6.58% |
| 2000-12-31 | -8.37% |
| 1999-12-31 | -15.22% |
| 1998-12-31 | -9.18% |
| 1997-12-31 | -20.70% |
| 1996-12-31 | -6.98% |
Related Metrics
About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Daniel O'Day